The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors
Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): V. Sahai, J.W. Valle, N. Fares, M. Javle, I. Ghanem, P. Cerdà, I.G. Rapposelli, I.G. Jimenez, M.A. Gonzalez-Carmona, A. Hollebecque, R. Pazo Cid, D.H. Palmer, R. Vera, A. Casadei-Gardini, D. Melisi, J.-F. Blanc, L. Perkhofer, A. Lamarca, H. Gharbi, V. Manuel-Minguez
The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826000671?dgcid=rss_sd_all
The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826000671?dgcid=rss_sd_all
“The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.” ESMO Gastrointestinal Oncology.
@article{article44844,
title = {The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826000671?dgcid=rss_sd_all}
}